Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2

被引:0
|
作者
Miao Miao
Yuhui Li
Bo Huang
Jing He
Zhanguo Li
机构
[1] Peking University People’s Hospital,Department of Rheumatology and Immunology
[2] Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135),Peking
[3] Peking University,Tsinghua Center for Life Sciences
来源
Dermatology and Therapy | 2020年 / 10卷
关键词
Hypomyopathic dermatomyositis; Refractory dermatitis; Low-dose IL-2;
D O I
暂无
中图分类号
学科分类号
摘要
Hypomyopathic dermatomyositis (DM) presents with cutaneous lesions consistent with dermatomyositis but in the absence of clinically appreciable muscle weakness. The cutaneous manifestations are often refractory and more resistant to conventional therapy than concomitant muscle involvement. We present a 61-year-old hypomyopathic patient with DM who failed to respond to standard therapy but was successfully treated by low-dose interleukin-2 (IL-2) with no significant side effects. We conclude that low-dose IL-2 is a safe and effective treatment for hypomyopathic DM.
引用
收藏
页码:1181 / 1184
页数:3
相关论文
共 50 条
  • [1] Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
    Miao, Miao
    Li, Yuhui
    Huang, Bo
    He, Jing
    Li, Zhanguo
    [J]. DERMATOLOGY AND THERAPY, 2020, 10 (05) : 1181 - 1184
  • [2] EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH MULTIPLE MYOSITIS/DERMATOMYOSITIS
    Sun, He-Hua
    Zhang, Sheng-xiao
    Wang, Jia
    Hao, Yu-Fei
    Liu, Guang-Ying
    Wang, Caihong
    Gao, Chong
    Li Xiao-Feng
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 201 - 201
  • [3] Low-dose IL-2 for SLE
    Thorley, Jennifer
    [J]. LANCET RHEUMATOLOGY, 2019, 1 (03): : E143 - E143
  • [4] Low-Dose IL-2 in the Treatment of Lupus
    Masayuki Mizui
    George C. Tsokos
    [J]. Current Rheumatology Reports, 2016, 18
  • [5] Low-Dose IL-2 in the Treatment of Lupus
    Mizui, Masayuki
    Tsokos, George C.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2016, 18 (11)
  • [6] Local low-dose IL-2 therapy
    Den Otter, W
    Balemans, L
    Battermann, JJ
    Bernsen, MR
    Cadee, JA
    Dobrowolski, Z
    Everse, LA
    Fiszer-Maliszewska, L
    Gavhumende, R
    De Groot, JW
    De Groot, K
    Hennink, WE
    Hill, FWG
    Jurgenliemp-Schulz, I
    Klein, WR
    Koten, JW
    Maas, RA
    Steerenberg, P
    Stewart, R
    Zembala, M
    [J]. HEPATO-GASTROENTEROLOGY, 1999, 46 : 1280 - 1286
  • [7] EFFICACY OF LOW-DOSE IL-2 IN PATIENTS WITH MYOSITIS
    Wang, X. M.
    Zhang, J. X.
    Chai, P. H.
    Li, Y. Z.
    Su, Q. Y.
    Yu, Q.
    He, P. F.
    Li, X.
    Zhang, S. X.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1671 - 1672
  • [8] Low-dose IL-2 therapy for autoimmune diseases
    Collison J.
    [J]. Nature Reviews Rheumatology, 2019, 15 (1) : 2 - 2
  • [9] Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2
    Churlaud, Guillaume
    Abbara, Chadi
    Vinot, Pierre-Axel
    Fourcade, Gwladys
    Ritvo, Paul-Gydeon
    Lorenzon, Roberta
    Rosenzwajg, Michelle
    Diquet, Bertrand
    Klatzmann, David
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (04) : 1344 - 1346
  • [10] Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
    Wang, Jia
    Sun, He-hua
    Zhang, Sheng-xiao
    Zhang, Jia-qian
    Bai, Jiang
    Luo, Jing
    Wang, Cai-hong
    Gao, Chong
    Li, Xiao-feng
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71